News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,113 Results
Type
Article (14251)
Company Profile (281)
Press Release (253581)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79531)
Career Advice (152)
Deals (13230)
Drug Delivery (35)
Drug Development (50462)
Employer Resources (31)
FDA (5724)
Job Trends (5133)
News (144435)
Policy (10032)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21673)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5752)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1479)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (117)
Cell therapy (331)
Cervical cancer (8)
Clinical research (41088)
Collaboration (542)
Compensation (258)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (164)
Cystic fibrosis (76)
Data (1523)
Denatured (11)
Depression (30)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29845)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48608)
Executive appointments (464)
FDA (6422)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1080)
Grass and pollen (2)
Guidances (22)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (101)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (53)
Medical device (2599)
Medtech (2600)
Mergers & acquisitions (6287)
Metabolic disorders (390)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1257)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (43)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (78)
Peanut (35)
People (25647)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14514)
Phase II (19111)
Phase III (12082)
Pipeline (808)
Policy (45)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8641)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (60)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (213)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (97)
Last 7 days (520)
Last 30 days (1519)
Last 365 days (19556)
2025 (6292)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17315)
Australia (2935)
California (3864)
Canada (1141)
China (360)
Colorado (149)
Connecticut (152)
Delaware (102)
Europe (37248)
Florida (466)
Georgia (116)
Idaho (16)
Illinois (232)
India (10)
Indiana (91)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (473)
Massachusetts (3083)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (968)
New Mexico (12)
New York (1045)
North Carolina (554)
North Dakota (5)
Northern California (1702)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (741)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1489)
Tennessee (25)
Texas (449)
United States (13275)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,113 Results for "oncomyx therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer
OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer.
March 2, 2022
·
4 min read
OncoMyx Presents New Data at AACR 2022 Demonstrating Multi-Armed Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune Responses
OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13.
April 8, 2022
·
3 min read
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads
OncoMyx is developing a next generation oncolytic virus platform including the capacity for multi-arming with a nonpathogenic virus which allows for intravenous (IV) and repeat dosing.
December 8, 2021
·
5 min read
Business
OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of Directors
OncoMyx Therapeutics, a privately held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors.
November 6, 2020
·
3 min read
AACR: OncoMyx Presents First Data Showing Myxoma Virotherapy Anti-Tumor Efficacy
The three posters OncoMyx Therapeutics presented at the virtual American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10th provided the first data indicating its myxoma virotherapy approach to oncolytic therapeutics.
April 12, 2021
·
4 min read
·
Gail Dutton
Business
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential
Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.
November 17, 2020
·
4 min read
·
Gail Dutton
BioMidwest
OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme Malignancies
OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced the presentation of new preclinical data at the Society for Immunotherapy of Cancer’s 36th Annual Meeting & Pre-Conference Programs being held November 10-14, 2021, both virtually and in Washington, D.C.
November 12, 2021
·
4 min read
BioMidwest
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
April 10, 2021
·
4 min read
OncoMyx Announces Assignment of Foundational Technology and Intellectual Property Portfolio for Oncolytic Myxoma Virus Technology
OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced today that The University of Western Ontario (Western) has assigned to OncoMyx the technology and patent rights associated with pioneering research on the use of myxoma virus in the treatment of cancer.
December 7, 2020
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 26,812
Next
